(0.18%) 5 109.30 points
(0.14%) 38 292 points
(0.21%) 15 962 points
(-1.05%) $82.97
(4.84%) $2.02
(0.09%) $2 349.40
(0.10%) $27.56
(4.19%) $960.70
(-0.18%) $0.933
(-0.31%) $10.99
(-0.46%) $0.797
(1.74%) $93.47
@ $5.43
发出时间: 10 Feb 2024 @ 04:55
回报率: -46.41%
上一信号: Feb 8 - 03:00
上一信号:
回报率: 5.44 %
Live Chart Being Loaded With Signals
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases...
Stats | |
---|---|
今日成交量 | 21 663.00 |
平均成交量 | 98 785.00 |
市值 | 5.89M |
EPS | $0 ( 2024-04-01 ) |
下一个收益日期 | ( $-2.41 ) 2024-05-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0600 |
ATR14 | $0.0270 (0.93%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Sapirstein James | Sell | 174 | Common Stock |
2024-04-01 | Romano Sarah | Sell | 75 | Common Stock |
2024-03-15 | Sapirstein James | Sell | 1 887 | Common Stock |
2024-03-15 | Romano Sarah | Sell | 1 120 | Common Stock |
2024-03-13 | Syage Jack | Buy | 15 400 | Common Stock, par value $0.0001 per share |
INSIDER POWER |
---|
93.62 |
Last 95 transactions |
Buy: 5 900 618 | Sell: 1 318 677 |
音量 相关性
First Wave BioPharma, 相关性 - 货币/商品
First Wave BioPharma, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2023 |
营收: | $0 |
毛利润: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2022 |
营收: | $0 |
毛利润: | $-106 207 (0.00 %) |
EPS: | $-461.72 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1 377.25 |
Financial Reports:
No articles found.
First Wave BioPharma,
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。